Patents by Inventor Patrick M. Hughes

Patrick M. Hughes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oil-in-Oil emulsified polymeric implants containing a hypotensive lipid and related methods
    Publication number: 20160243131
    Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Application
    Filed: May 2, 2016
    Publication date: August 25, 2016
    Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
  • Hypotensive lipid-containing biodegradable intraocular implants and related methods
    Patent number: 9393223
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: July 19, 2016
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT
    Publication number: 20160199387
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Application
    Filed: March 21, 2016
    Publication date: July 14, 2016
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS
    Publication number: 20160199297
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol.
    Type: Application
    Filed: January 11, 2016
    Publication date: July 14, 2016
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Method of making oil-in-oil emulsified polymeric implants containing a hypotensive lipid
    Patent number: 9326949
    Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: May 3, 2016
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
  • Prostamide-containing intraocular implant
    Patent number: 9289413
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 22, 2016
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • DERMAL FILLER
    Publication number: 20160038396
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Application
    Filed: October 19, 2015
    Publication date: February 11, 2016
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR TREATING OCULAR VASCULOPATHIES
    Publication number: 20160038654
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Application
    Filed: October 19, 2015
    Publication date: February 11, 2016
    Inventors: Glenn T. Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn
  • FORMULATIONS OF BIOLOGICS FOR INTRAVESICAL INSTILLATION
    Publication number: 20160030570
    Abstract: Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.
    Type: Application
    Filed: July 30, 2015
    Publication date: February 4, 2016
    Inventors: Eric A. Forssen, Patrick M. Hughes, David C. Rupp
  • SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR PREVENTING RETINAL DYSFUNCTION
    Publication number: 20160008354
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.
    Type: Application
    Filed: September 22, 2015
    Publication date: January 14, 2016
    Inventors: Glenn T. Huang, James A. Burke, Patrick M. Hughes, Kai-Ming Zhang, Ton Lin, Larry A. Wheeler, Rosy Sheng Donn
  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 9233070
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: January 12, 2016
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • FORMULATIONS OF BIOLOGICS FOR INTRAVESICAL INSTILLATION
    Publication number: 20150313973
    Abstract: Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.
    Type: Application
    Filed: April 30, 2015
    Publication date: November 5, 2015
    Inventors: Eric A. Forssen, Patrick M. Hughes, David C. Rupp, Terrence Hunt, Gary Shimizu, Joseph Francis, Ron S. Broide, Ester Fernandez-Salas
  • Sustained release intraocular implants and methods for treating ocular vasculopathies
    Patent number: 9161938
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: October 20, 2015
    Assignee: Allergan, Inc.
    Inventors: Glenn T. Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn
  • Dermal filler
    Patent number: 9161970
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: October 20, 2015
    Assignee: Allergan, Inc.
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • KETOROLAC-CONTAINING SUSTAINED RELEASE DRUG DELIVERY SYSTEMS
    Publication number: 20150290170
    Abstract: Biodegradable intraocular drug delivery systems comprising ketorolac and a biodegradable polymer matrix that can release ketorolac into an eye for an extended period of time at a substantially constant rate are described.
    Type: Application
    Filed: October 24, 2013
    Publication date: October 15, 2015
    Applicant: ALLERGAN, INC.
    Inventors: Hui Liu, Kun Xu, Patrick M. Hughes
  • Oil-in-Oil emulsified polymeric implants containing a hypotensive lipid and related methods
    Publication number: 20150272898
    Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Application
    Filed: April 6, 2015
    Publication date: October 1, 2015
    Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
  • KETOROLAC-CONTAINING SUSTAINED RELEASE DRUG DELIVERY SYSTEMS
    Publication number: 20150272877
    Abstract: Biodegradable intraocular and intraarticular drug delivery systems comprising ketorolac and a biodegradable polymer matrix that can release ketorolac into an eye or joint for an extended period of time are described. The drug delivery systems may be in the form of an extruded implant and may be used to treat one or more medical and ocular conditions, such as post-operative pain and inflammation following an ocular surgery such as cataract surgery.
    Type: Application
    Filed: October 24, 2013
    Publication date: October 1, 2015
    Inventors: Ruiwen Shi, Patrick M. Hughes, Rhett M. Schiffman
  • Sustained release intraocular implants and methods for preventing retinal dysfunction
    Patent number: 9144543
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: September 29, 2015
    Assignee: Allergan, Inc.
    Inventors: Glenn T. Huang, James A. Burke, Patrick M. Hughes, Kai-Ming Zhang, Ton Lin, Larry A. Wheeler, Rosy Sheng
  • STEROID CONTAINING DRUG DELIVERY SYSTEM
    Publication number: 20150265633
    Abstract: Pharmaceutical composition for intraocular use comprising a glucocorticoid derivative, such as beclomethasone 17,21-diproprionate admixed with a biodegradable polymer such as a poly(lactide-co-glycolide) polymer or a high molecular weight polymeric hyaluronic acid are disclosed.
    Type: Application
    Filed: June 4, 2015
    Publication date: September 24, 2015
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison, Patrick M. Hughes, Lon T. Spada
  • Intraocular biodegradable microspheres
    Patent number: 9056045
    Abstract: Biocompatible intraocular microspheres can include an active agent and a biodegradable polymer that is effective to facilitate release of the active agent into the vitreous of an eye for an extended period of time. The therapeutic agent of the microsphere can be associated with a biodegradable polymer matrix and can be made by crystallizing the active agent in the matrix. the resulting biodegradable microspheres can be placed into an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: June 16, 2015
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Christian Sarrazin, Elisabeth Rossi, Michele Boix